Stifel Financial
IKT icon

Stifel Financial’s Inhibikase Therapeutics IKT Stock Holding History

Stifel Financial’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,129
Closed -$28.8K – 3524
2025
Q1 		$28.8K Hold
13,129
– – ﹤0.01% 3377
2024
Q4 		$42.7K Buy
+13,129
New +$32.8K ﹤0.01% 3323

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Stifel Financial's IKT Position: Q2 2025 in Review

Stifel Financial sold out of Inhibikase Therapeutics (IKT) in Q2 2025, closing a stake of 13,129 shares — an estimated $28.8K sold.

Stifel Financial first reported a position in IKT in Q4 2024 and held it in 2 quarters. The position peaked at $42.7K in Q4 2024. 48 funds tracked by Wall St. Rank hold IKT as of Q2 2025.

  • Stifel Financial reported no remaining Inhibikase Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stifel Financial sold 13,129 Inhibikase Therapeutics shares in Q2 2025, an estimated $28.8K.
  • Stifel Financial first reported a position in Inhibikase Therapeutics in Q4 2024 and held it in 2 quarters.
  • Stifel Financial's Inhibikase Therapeutics position peaked at $42.7K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2025.

Based on Stifel Financial's 13F filing for Q2 2025, filed 14 Aug 2025.